Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Age does not appear to affect efficacy of siponimod in secondary progressive MS

Publish date:: March 10, 2020

Key clinical point: Siponimod has similar efficacy and safety in older and younger patients with secondary progressive MS.

Major finding: Compared with placebo, siponimod reduced the risk of 3-month confirmed disability progression by 32% in patients younger than 45 years and by 31% in patients age 45 years or older.

Study details: A post hoc analysis of 1,651 patients with secondary progressive MS enrolled in the EXPAND study.

Disclosures: Novartis funded the study. Dr. Hua received fees from Novartis, Biogen, Celgene, EMD Serono, Genentech, and Genzyme.

Citation:

Hua L et al. ACTRIMS FORUM 2020, Abstract P029.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,